About
BioTerm Pharmaceuticals develops therapeutics for the prevention of preterm labor and for the induction of labor. The company has developed the patent-pending Preventerm molecule for the prevention of preterm labor and the patented Inducterm molecule for labor induction. Preventerm is designed to block three of the five factors that prepare the cervix for labor, representing an effective multistep inhibition of the enzymes that begin the labor process. By attacking metalloproteinases and cytokine precursors, Preventerm interrupts several steps in the biological pathway, thereby preventing labor for up to a week, with 90% efficacy. Inducterm works by the reverse process, providing collagenase to begin the breakdown of cervical proteins and thereby inducing labor in three to five hours. Both of the companys drugs are based on scientifically and clinically proven molecules that are safe, inexpensive, and easily administered with minimal side effects. BioTerm Pharmaceuticals is currently seeking an equity investment to broaden management and to enhance marketing and business development activities in the U.S. and Europe.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals develops therapeutics for the prevention of preterm labor and for the induction of labor.
- What is the operational status of BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals is currently inactive and ceased to operate in July 2019.
- What are the two main products developed by BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals developed Preventerm, a patent-pending molecule for preventing preterm labor, and Inducterm, a patented molecule for labor induction.
- Where is BioTerm Pharmaceuticals headquartered?
- BioTerm Pharmaceuticals is headquartered in Tel Aviv-Yafo, Israel.
- When was BioTerm Pharmaceuticals founded?
- BioTerm Pharmaceuticals was founded in January 2002.
- What was the former name of BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals was formerly known as S.I. Biotechnology.
- What is the current funding stage of BioTerm Pharmaceuticals?
- BioTerm Pharmaceuticals is currently in the Pre-Funding stage and was seeking equity investment to broaden management and enhance marketing and business development activities in the U.S. and Europe.
- How many employees did BioTerm Pharmaceuticals have?
- BioTerm Pharmaceuticals had 6 employees.
- What is the primary sector of BioTerm Pharmaceuticals?
- The primary sector of BioTerm Pharmaceuticals is Health Tech & Life Sciences.